# Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)

> **NCT00141739** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 100 (actual)

## Conditions studied

- Graft-Versus-Host Disease

## Interventions

- **DRUG:** Etanercept

## Key facts

- **NCT ID:** NCT00141739
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2011-08
- **Final completion:** 2012-09
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-01-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00141739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00141739, "Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00141739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*